Novel IRAK4 Inhibitors for Treating Asthma

Sabnis, R. W.

doi:10.1021/acsmedchemlett.2c00324

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While Th17 cells are strongly associated with AR ( 101 ). Because of the important role of IRAK4 in triggering allergic inflammation, IRAK4 inhibitors could be targets for anti-inflammatory drugs ( 102 , 103 ). Deletion or inactivation of IRAK4 attenuates the development of inflammation ( 104 ).…”

Section: Tlr4/irak4/nf-κb Signaling Pathway and Armentioning

confidence: 99%

Tolerogenic dendritic cells and TLR4/IRAK4/NF-κB signaling pathway in allergic rhinitis

Kang,

Li,

Liu

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Dendritic cells (DCs), central participants in the allergic immune response, can capture and present allergens leading to allergic inflammation in the immunopathogenesis of allergic rhinitis (AR). In addition to initiating antigen-specific immune responses, DCs induce tolerance and modulate immune homeostasis. As a special type of DCs, tolerogenic DCs (tolDCs) achieve immune tolerance mainly by suppressing effector T cell responses and inducing regulatory T cells (Tregs). TolDCs suppress allergic inflammation by modulating immune tolerance, thereby reducing symptoms of AR. Activation of the TLR4/IRAK4/NF-κB signaling pathway contributes to the release of inflammatory cytokines, and inhibitors of this signaling pathway induce the production of tolDCs to alleviate allergic inflammatory responses. This review focuses on the relationship between tolDCs and TLR4/IRAK4/NF-κB signaling pathway with AR.

show abstract

Section: Tlr4/irak4/nf-κb Signaling Pathway and Armentioning

confidence: 99%

Tolerogenic dendritic cells and TLR4/IRAK4/NF-κB signaling pathway in allergic rhinitis

Kang,

Li,

Liu

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Other studies displayed the preparation of an anti-asthmatic drug (fevipiprant) through of DP2-receptor inhibition (Sandham et al, 2017). In addition, a series of anti-asthmatic agents (indazole-5-carboxamide derivatives) were developed with biological activity on IRAK4 (interleukin-1 receptor-associated kinase 4) (Sabnis et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Interaction of twenty-two carbazole derivatives with M1-muscarinic receptor using a theoretical model

Figueroa-Valverde,

López-Ramos,

Rosas-Nexticapa

et al. 2024

Braz. J. of Sci.

View full text Add to dashboard Cite

Several drugs have been used to treat asthma diseases, such as salmeterol, ipratropium bromide, montelukast, and fluticasone; however, some of these drugs can cause side effects such as hypokalemia, lactic acidosis, and hypotension. Analyzing these data, this study aimed to evaluate the possible interaction of twenty-two carbazole derivatives with the M1-muscrinic receptor to provide a new therapeutic alternative against asthma. The theoretical interaction of carbazole derivatives with M1-muscrinic receptor surface was determined using 5cxv protein, pirenzepine, atropine, AF-150, and PD159714 drugs as theoretical tools in a DockingServer software. The results showed differences in the interaction of carbazole derivatives with the 5cxv protein surface compared with pyranzepine, atropine, AF-150, and PD159714 drugs. Besides, constant inhibition (Ki) for carbazole derivatives 11 and 22 was lower than for pirenzepine and AF-150 drugs. Other data indicate that Ki values for 11 and 22 were higher than atropine and ipratropium bromide. In addition, the Ki values for compounds 17 and 20 were like both atropine and PD150714 drugs. Finally, Ki values for carbazole derivatives 17 and 20 were lower than pyranzepine, ipratropium bromide, and AF-150 reagents. All these data suggest that carbazole derivatives 11, 17, 20, and 22 may act as M1-muscarinic receptor inhibitor agents; this phenomenon could result in the regulation of bronchial tone in asthma disease.

show abstract

The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases

Bai

Yang

Hou

et al. 2023

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

Novel IRAK4 Inhibitors for Treating Asthma

Cited by 3 publications

References 6 publications

Tolerogenic dendritic cells and TLR4/IRAK4/NF-κB signaling pathway in allergic rhinitis

Tolerogenic dendritic cells and TLR4/IRAK4/NF-κB signaling pathway in allergic rhinitis

Interaction of twenty-two carbazole derivatives with M1-muscarinic receptor using a theoretical model

The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases

Contact Info

Product

Resources

About